CTSC deficiency has been shown to attenuate the severity of pancreatitis, not by inhibiting proenzyme activation in acinar cells but by reducing neutrophil infiltration into the pancreas.198 B22, a novel indolinone derivative, inhibits CTSC activity and has been reported to reduce both inflammation and cytokine levels,199 highlighting CTSC as a potential therapeutic target for limiting disease progression in pancreatitis. This evidence concerns the gene CTSC and pancreatitis.